When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen to the conference call will be able to access a replay via our website at investors.davita.com. There will be no telephone replay. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients g ...

Company Overview - DaVita HealthCare (DVA) has a current PEG ratio of 1.04, which is lower than the Medical - Outpatient and Home Healthcare industry's average PEG ratio of 2.03 [2] - The company's stock has decreased by 3.75% over the past month, underperforming the Medical sector's gain of 0.71% and the S&P 500's gain of 3.82% [9] - As of the latest market close, DaVita HealthCare's stock price was $137.72, reflecting a daily increase of 1.3%, which outperformed the S&P 500's daily gain of 0.64% [10] Financial Performance - The Zacks Consensus Estimates project DaVita HealthCare's earnings for the full year to be $9.62 per share, representing a 13.58% increase from the prior year, with revenue expected to reach $12.74 billion, a 4.97% increase [4] - The upcoming earnings per share (EPS) is projected at $2.47, indicating an 18.75% increase compared to the same quarter of the previous year, with revenue estimated at $3.16 billion, up 5.43% from the prior-year quarter [12] Valuation Metrics - DaVita HealthCare's Forward P/E ratio is 14.13, which is a discount compared to the industry's average Forward P/E of 23.15 [11] Industry Context - The Medical - Outpatient and Home Healthcare industry has a Zacks Industry Rank of 60, placing it in the top 24% of over 250 industries [7] - The Zacks Industry Rank indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [3]

Core Viewpoint - DaVita is experiencing strong growth driven by its dialysis services and strategic acquisitions, leading to improved financial performance and optimism for future expansion [2][3][11]. Group 1: Company Overview - DaVita is a leading provider of dialysis services in the United States, catering to patients with chronic kidney failure through a network of outpatient dialysis centers and related medical services [1]. - As of March 31, 2024, DaVita served approximately 258,600 patients across 3,092 outpatient dialysis centers, with 2,665 located in the U.S. and 427 in 12 other countries [5]. Group 2: Financial Performance - The company's first-quarter 2024 results showed improvements in both top and bottom lines, with notable strength in dialysis patient services and other revenues [3]. - DaVita's shares have increased by 29.8% year-to-date, outperforming the industry growth of 8% and the S&P 500's rise of 17% [11]. Group 3: Growth Catalysts - The optimism surrounding DaVita is fueled by a solid first-quarter performance and the potential for further growth through strategic collaborations and acquisitions of dialysis centers [2][11]. - DaVita has extended its supply and collaboration agreement with Nuwellis, which may lead to a long-term partnership for ultrafiltration services [4]. Group 4: International Expansion - The company is actively expanding its international presence, with recent agreements to enhance operations in Brazil and Colombia, and to enter Chile and Ecuador [14]. - DaVita has solidified its position in various international markets, including China, Germany, and India, through strategic collaborations and acquisitions [6]. Group 5: Business Strategy - DaVita's preferred business strategy involves acquiring dialysis centers and related services, which has significantly boosted its revenue and investor confidence [13]. - The company is focusing on a patient-centric care model that enhances collaboration among nephrologists and providers, aiming for improved care coordination and early intervention [12].

Core Insights - The global renal denervation devices market was valued at USD 54.26 million in 2023 and is projected to reach USD 387 million by 2032, growing at a CAGR of 37.2% from 2024 to 2032 [1][11]. Market Drivers - The increasing prevalence of hypertension, particularly among the aging population, is expected to drive demand for renal denervation devices [2][16]. - Lifestyle factors such as smoking and poor dietary habits are contributing to the rise in hypertension cases, further boosting market demand [4][9]. - Innovative research and development in hypertension treatment are creating new commercial opportunities, with successful studies on devices like the Peregrine System Infusion Catheter demonstrating safety and efficacy [8][16]. Regional Insights - Europe holds the largest market share for renal denervation devices, with an estimated CAGR of 37.5% during the forecast period, driven by a growing geriatric population and increasing cases of therapy-resistant hypertension [9][10]. - The Asia-Pacific region is expected to account for USD 90 million by 2030, with a CAGR of 37.6%, fueled by rising hypertension prevalence and awareness of treatment benefits [20]. Market Segmentation - The renal denervation devices market is segmented by technology into Radiofrequency-based, Ultrasound-based, and Micro-infusion-based, with Radiofrequency-based devices holding the largest market share and a projected CAGR of 37.1% [11][23]. - The market is also segmented by end users, including hospitals, clinics, and ambulatory surgery centers [23]. Competitive Landscape - Key players in the renal denervation devices market include Medtronic PLC, St. Jude Medical Inc., ReCor Medical Inc., and Ablative Solutions Inc., among others [22]. - Companies are focusing on R&D, mergers and acquisitions, and product launches to enhance their market position [10].

Company Performance - DaVita HealthCare (DVA) shares experienced a loss of 2.97% over the previous month, underperforming the Medical sector's loss of 1.99% and the S&P 500's gain of 4.34% [1] - In the latest trading session, DaVita HealthCare closed at $137.92, reflecting a +0.39% move from the prior day, outperforming the S&P 500's daily gain of 0.07% [6] - The upcoming earnings disclosure is projected to show earnings of $2.47 per share, indicating year-over-year growth of 18.75%, with a revenue estimate of $3.16 billion, representing a 5.43% rise from the same quarter last year [7] Financial Estimates - For the entire fiscal year, earnings are projected at $9.62 per share and revenue at $12.74 billion, reflecting changes of +13.58% and +4.97% from the prior year, respectively [2] - DaVita HealthCare currently has a Forward P/E ratio of 14.27, which is below the industry average Forward P/E of 22.5, indicating it is trading at a discount compared to its peers [9] Analyst Insights - Recent changes to analyst estimates for DaVita HealthCare are important as they reflect short-term business trends, with positive revisions indicating analysts' confidence in the company's performance [8] - The Zacks Rank system rates DaVita HealthCare at 2 (Buy), with a track record of delivering an average annual return of +25% for stocks rated 1 since 1988 [11] Industry Context - The Medical - Outpatient and Home Healthcare industry, which includes DaVita HealthCare, has a current Zacks Industry Rank of 52, placing it in the top 21% of over 250 industries [12]

Company Overview - DaVita HealthCare (DVA) ended the latest trading session at $142.16, reflecting a -0.53% adjustment from the previous day's close, underperforming the S&P 500's 0.16% gain [3] - Over the last month, DaVita's shares decreased by 0.52%, while the Medical sector gained 2.32% and the S&P 500 increased by 3.22% [3] Earnings Performance - DaVita is expected to report an EPS of $2.47, indicating an 18.75% growth compared to the same quarter last year [4] - The consensus estimate for revenue is $3.16 billion, showing a 5.43% increase compared to the year-ago quarter [4] - For the entire year, the Zacks Consensus Estimates forecast earnings of $9.62 per share and revenue of $12.74 billion, reflecting changes of +13.58% and +4.97% respectively compared to the previous year [5] Analyst Estimates and Rankings - Recent changes to analyst estimates for DaVita HealthCare suggest positive business outlooks, as these revisions often reflect short-term business dynamics [5] - DaVita currently holds a Zacks Rank of 2 (Buy), with no change in the Zacks Consensus EPS estimate over the past month [6] Valuation Metrics - DaVita HealthCare is trading at a Forward P/E ratio of 14.85, which is a discount compared to the industry average Forward P/E of 23.18 [7] - The company has a PEG ratio of 1.09, compared to the industry average PEG ratio of 1.96 [7] Industry Context - The Medical - Outpatient and Home Healthcare industry, which includes DaVita, has a Zacks Industry Rank of 27, placing it in the top 11% of over 250 industries [8] - The Zacks Industry Rank measures the strength of industry groups based on the average Zacks Rank of individual stocks, indicating that top-rated industries outperform the bottom half by a factor of 2 to 1 [8]

Company Overview - DaVita Inc. is a leading provider of dialysis services in the U.S. for patients suffering from chronic kidney failure, operating kidney dialysis centers and providing related medical services primarily in dialysis centers and contracted hospitals across the U.S. [10] - The company's services include outpatient dialysis services, hospital inpatient dialysis services, and ancillary services such as ESRD laboratory services and disease management services [10]. Investment Ratings - DaVita Inc. holds a Zacks Rank of 2 (Buy) and has a VGM Score of A, indicating strong potential for investment [11]. - The company is also considered a top pick for growth investors, with a Growth Style Score of B, forecasting year-over-year earnings growth of 13.6% for the current fiscal year [11]. Earnings Estimates - In the last 60 days, three analysts have revised their earnings estimates upwards for fiscal 2024, with the Zacks Consensus Estimate increasing by $0.39 to $9.62 per share [11]. - DaVita boasts an average earnings surprise of 29.4%, indicating a strong performance relative to expectations [11]. Conclusion - With a solid Zacks Rank and top-tier Growth and VGM Style Scores, DaVita Inc. is recommended for investors' consideration [12].

Denver, CO-headquartered DaVita is a leading provider of dialysis services in the United States to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services, primarily in dialysis centers and contracted hospitals across the country. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease mana ...

Thus, at the moment, investing in service-oriented companies like CareCloud, Inc. (CCLD) , DaVita Inc. (DVA) , RadNet, Inc. (RDNT) , SkyWest, Inc. (SKYW) and American Express Company (AXP) seems judicious. The NMI, incidentally, had fallen into the contraction territory for the first time in April since December 2022. Any reading below the 50% mark indicates a contraction. The business activity index increased to 61.2% in May from 50.9% in April and expanded for the 48th successive month. The index has notc ...

DaVita (DVA) recently extended the pilot phase of a previously announced supply and collaboration agreement with Nuwellis until Aug 31, 2024.At the conclusion of the pilot phase, DaVita may extend the supply agreement with Nuwellis for continued provision of both inpatient and outpatient ultrafiltration services for up to 10 years. Price Performance Image Source: Zacks Investment Research In June 2023, DaVita and Nuwellis entered into a supply and collaboration agreement for the use of Aquadex ultrafiltrati ...